AI assistant
VERTEX PHARMACEUTICALS INC / MA — Director's Dealing 2021
Feb 5, 2021
29864_dirs_2021-02-05_e86b8837-feb8-4317-8f5d-ee71436aecd4.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: VERTEX PHARMACEUTICALS INC / MA (VRTX)
CIK: 0000875320
Period of Report: 2021-02-03
Reporting Person: Kewalramani Reshma (Director, CEO & President)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2021-02-03 | Common Stock | A | 3516 | $0.00 | Acquired | 30164 | Direct |
| 2021-02-03 | Common Stock | A | 12388 | $0.00 | Acquired | 42552 | Direct |
| 2021-02-03 | Common Stock | A | 29031 | $0.00 | Acquired | 71583 | Direct |
Footnotes
F1: Represents earned performance shares with respect to a performance stock unit award granted on 02/06/2018 that contained performance-vesting requirements. The issuer's management development and compensation committee certified as to the level of performance-goal attainment on 02/03/2021 and the shares will vest on 02/17/2021.
F2: Represents earned performance shares with respect to a performance stock unit award granted on 02/05/2020 that contained performance-vesting requirements. The issuer's management development and compensation committee certified as to the level of performance-goal attainment on 02/03/2021 and the shares will vest in installments beginning on 02/10/2021.
F3: Restricted stock unit award that vests in installments beginning on 02/17/2022.